Premature Ejaculation - Pipeline Review, H1 2018

  • ID: 4518526
  • Drug Pipelines
  • 44 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Ixchelsis Ltd
  • N4 Pharma Plc
  • Regent Pacific Group Ltd
  • SK Chemicals Co Ltd
  • MORE
Premature Ejaculation - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Premature Ejaculation - Pipeline Review, H1 2018, provides an overview of the Premature Ejaculation (Male Health) pipeline landscape.

Premature ejaculation (PE) is also known as rapid ejaculation, is the most common type of sexual dysfunction in men. Ejaculation is controlled by the central nervous system. This happens when sexual stimulation and friction provide impulses that are delivered to the spinal cord and into the brain. The predisposing factors include erectile dysfunction, stress and certain medications that influence the action of chemical messengers in the brain (psychotropics) may contribute to premature ejaculation. Treatment includes topical anesthetic creams and antidepressants.

Report Highlights:

This latest pipeline guide Premature Ejaculation - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Premature Ejaculation (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Premature Ejaculation (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Ejaculation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 4 and 1 respectively.

Premature Ejaculation (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Premature Ejaculation (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Premature Ejaculation (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Premature Ejaculation (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Premature Ejaculation (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Premature Ejaculation (Male Health)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Premature Ejaculation (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Premature Ejaculation (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Ixchelsis Ltd
  • N4 Pharma Plc
  • Regent Pacific Group Ltd
  • SK Chemicals Co Ltd
  • MORE
Introduction

Report Coverage

Premature Ejaculation - Overview

Premature Ejaculation - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Premature Ejaculation - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Premature Ejaculation - Companies Involved in Therapeutics Development

Ixchelsis Ltd

Kuhnil Pharmaceutical Co Ltd

N4 Pharma Plc

NeuroHealing Pharmaceuticals Inc

Regent Pacific Group Ltd

SK Chemicals Co Ltd

Premature Ejaculation - Drug Profiles

(lidocaine hydrochloride + prilocaine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

duloxetine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IX-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KI-251 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

libiguins - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

modafinil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCE-405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Premature Ejaculation - Dormant Projects

Premature Ejaculation - Discontinued Products

Premature Ejaculation - Product Development Milestones

Featured News & Press Releases

Jan 25, 2016: Ixchelsis Announces Positive Clinical Proof of Concept Results for IX-01 in Treating Premature Ejaculation

Nov 11, 2014: Plethora Solutions Provides Company Update

Oct 07, 2014: PSD502 To Be Marketed As Fortacin Throughout The EU

Mar 26, 2014: Plethora Solutions Announces Manufacturing Appointment

Mar 11, 2014: Plethora Solutions Provides Company update

Nov 19, 2013: Plethora Solutions Receives European Commission Approval For PSD502 To Treat Premature Ejaculation

Sep 19, 2013: Plethora Solutions Receives CHMP Positive Opinion For Lidocaine/Prilocaine Plethora For Treatment Of Primary Premature Ejaculation

Jul 01, 2013: AGM Statement & PSD502 Regulatory Update

Jun 11, 2012: Plethora Provides PSD502 Regulatory Submission Update

Mar 15, 2012: Plethora Provides Update On Regulatory Submission Of PSD

Dec 19, 2011: Plethora Provides Update On PSD

Jun 01, 2010: Shionogi Pharma Presents Data On PSD502 For Primary Premature Ejaculation

May 26, 2010: Shionogi Pharma Announces Five Clinical Presentations On PSD502 For Primary Premature Ejaculation At AUA Annual Meeting

Nov 19, 2009: Sciele Pharma Presents Pivotal Study For PSD502, The First Potential Treatment For Premature Ejaculation At The Sexual Medicine Society Of North America (SMSNA)

Aug 21, 2009: NeuroHealing Announces Formation Of Medical Advisory Board For NH02D Program

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Premature Ejaculation, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Premature Ejaculation - Pipeline by Ixchelsis Ltd, H1 2018

Premature Ejaculation - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2018

Premature Ejaculation - Pipeline by N4 Pharma Plc, H1 2018

Premature Ejaculation - Pipeline by NeuroHealing Pharmaceuticals Inc, H1 2018

Premature Ejaculation - Pipeline by Regent Pacific Group Ltd, H1 2018

Premature Ejaculation - Pipeline by SK Chemicals Co Ltd, H1 2018

Premature Ejaculation - Dormant Projects, H1 2018

Premature Ejaculation - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Premature Ejaculation, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Ixchelsis Ltd
  • Kuhnil Pharmaceutical Co Ltd
  • N4 Pharma Plc
  • NeuroHealing Pharmaceuticals Inc
  • Regent Pacific Group Ltd
  • SK Chemicals Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll